Business
Eko Appoints Renee Gaeta as Chief Financial Officer
Gaeta, a seasoned medical technology executive joins the company as it continues its product and healthcare market expansion OAKLAND, Calif., Aug. 02, 2021
About this update from Establishment Labs Holdings Inc.
[{"type":"text","content":"Gaeta, a seasoned medical technology executive joins the company as it continues its product and healthcare market expansion\nOAKLAND, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Eko, a cardiopulmonary digital health company, today announced the appointment of Renee Gaeta as Chief Financial Officer (CFO) and member of the executive leadership team. “Eko is at a key moment in its journey to build a comprehensive platform for digital cardiopulmonary care.” said Connor Landgraf, CEO and co-founder of Eko. “Renee’s experience in guiding global public and private medical technology companies through sustained stages of high growth is ideal for Eko. Her strategic vision and knowledge of finance and healthcare will help us expand our impact on patient care.” Mrs. Gaeta previously served as CFO and member of the executive team at Establishment Labs Holdings, Inc. (NASDAQ: ESTA), where she played a key role in the company’s successful Initial Public Offering (IPO) and Follow-On Offering. Revenue more than tripled during her tenure, as did the company’s valuation after the IPO, they grew direct sales in addition to distributor revenue, launched new products and expanded markets, and ran an FDA clinical trial for a Class III device. Prior to Establishment Labs, Mrs. Gaeta was Vice President, Corporate Controller and executive team member at Sientra, Inc. (NASDAQ: SIEN). In this role she was instrumental in preparing the company during its pre-IPO stage, establishing compliant systems and controls, and she also played a key role in the company’s successful IPO and Follow-On Offering. Previously, Mrs. Gaeta spent ten years with KPMG, LLP, rising through the organization to the role of Director, Transaction & Restructuring. Mrs. Gaeta joins Eko during a period of significant company milestones. The U.S. Food and Drug Administration (FDA) cleared Eko’s artificial intelligence (AI) algorithms for detecting heart murmurs and atrial fibrillation, and also issued an Emergency Use Authorization (EUA) for Eko’s novel rapid screening test for low ejection fraction (low EF), a weak heart pump. Eko launched the first AI-powered cardiopulmonary telehealth platform for virtual physical exams. Eko and 3M™ Littmann® Stethoscopes launched a collaboration of the Littmann CORE Digital Stethoscope that marries best-in-class 3M Littmann stethoscope technology wit...